These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 18819053)

  • 21. Recent studies with eplerenone, a novel selective aldosterone receptor antagonist.
    McMahon EG
    Curr Opin Pharmacol; 2001 Apr; 1(2):190-6. PubMed ID: 11714095
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mineralocorticoid and angiotensin receptor antagonism during hyperaldosteronemia.
    Mihailidou AS; Mardini M; Funder JW; Raison M
    Hypertension; 2002 Aug; 40(2):124-9. PubMed ID: 12154101
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Endothelial mineralocorticoid receptor activation mediates endothelial dysfunction in diet-induced obesity.
    Schäfer N; Lohmann C; Winnik S; van Tits LJ; Miranda MX; Vergopoulos A; Ruschitzka F; Nussberger J; Berger S; Lüscher TF; Verrey F; Matter CM
    Eur Heart J; 2013 Dec; 34(45):3515-24. PubMed ID: 23594590
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: Beneficial effects of mineralocorticoid receptor blocker.
    Ohtani T; Ohta M; Yamamoto K; Mano T; Sakata Y; Nishio M; Takeda Y; Yoshida J; Miwa T; Okamoto M; Masuyama T; Nonaka Y; Hori M
    Am J Physiol Regul Integr Comp Physiol; 2007 Feb; 292(2):R946-54. PubMed ID: 17023667
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aldosterone Synthase Inhibition Improves Glucose Tolerance in Zucker Diabetic Fatty (ZDF) Rats.
    Hofmann A; Brunssen C; Peitzsch M; Martin M; Mittag J; Jannasch A; Engelmann F; Brown NF; Weldon SM; Huber J; Streicher R; Deussen A; Eisenhofer G; Bornstein SR; Morawietz H
    Endocrinology; 2016 Oct; 157(10):3844-3855. PubMed ID: 27526033
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of aldosterone and related steroids on LPS-induced increased expression of inducible NOS in rat aortic smooth muscle cells.
    Godfrey V; Martin AL; Struthers AD; Lyles GA
    Br J Pharmacol; 2011 Dec; 164(8):2003-14. PubMed ID: 21649641
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gene expression effects of glucocorticoid and mineralocorticoid receptor agonists and antagonists on normal human skeletal muscle.
    Chadwick JA; Hauck JS; Gomez-Sanchez CE; Gomez-Sanchez EP; Rafael-Fortney JA
    Physiol Genomics; 2017 Jun; 49(6):277-286. PubMed ID: 28432191
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism.
    Eudy RJ; Sahasrabudhe V; Sweeney K; Tugnait M; King-Ahmad A; Near K; Loria P; Banker ME; Piotrowski DW; Boustany-Kari CM
    J Transl Med; 2011 Oct; 9():180. PubMed ID: 22017794
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relative inhibitory potency of five mineralocorticoid antagonists on aldosterone biosynthesis in vitro.
    Netchitailo P; Delarue C; Perroteau I; Leboulenger F; Capron MH; Vaudry H
    Biochem Pharmacol; 1985 Jan; 34(2):189-94. PubMed ID: 2981534
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adrenal gland inclusions in patients treated with aldosterone antagonists (Spironolactone/Eplerenone): incidence, morphology, and ultrastructural findings.
    Patel KA; Calomeni EP; Nadasdy T; Zynger DL
    Diagn Pathol; 2014 Aug; 9():147. PubMed ID: 25108298
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential actions of eplerenone and spironolactone on the protective effect of testosterone against cardiomyocyte apoptosis in vitro.
    Sánchez-Más J; Turpín MC; Lax A; Ruipérez JA; Valdés Chávarri M; Pascual-Figal DA
    Rev Esp Cardiol; 2010 Jul; 63(7):779-87. PubMed ID: 20609311
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of eplerenone versus spironolactone on cortisol and hemoglobin A₁(c) levels in patients with chronic heart failure.
    Yamaji M; Tsutamoto T; Kawahara C; Nishiyama K; Yamamoto T; Fujii M; Horie M
    Am Heart J; 2010 Nov; 160(5):915-21. PubMed ID: 21095280
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Eplerenone antagonizes atherosclerosis, but what is the agonist?
    Strawn WB
    Hypertension; 2005 Nov; 46(5):1093-4. PubMed ID: 16216993
    [No Abstract]   [Full Text] [Related]  

  • 34. Low-dose spironolactone prevents apoptosis repressor with caspase recruitment domain degradation during myocardial infarction.
    Loan Le TY; Mardini M; Howell VM; Funder JW; Ashton AW; Mihailidou AS
    Hypertension; 2012 Jun; 59(6):1164-9. PubMed ID: 22508833
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Aldosterone and its antagonists in heart failure].
    Lopes ME; Le Corvoisier P; Tabet JY; Su JB; Badoual T; Cachin JC; Merlet P; Castaigne A; Hittinger L
    Presse Med; 2003 Jan; 32(2):79-87. PubMed ID: 12653034
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aldosterone and cortisol predict medium-term left ventricular remodelling following myocardial infarction.
    Weir RA; Tsorlalis IK; Steedman T; Dargie HJ; Fraser R; McMurray JJ; Connell JM
    Eur J Heart Fail; 2011 Dec; 13(12):1305-13. PubMed ID: 21940729
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Central mineralocorticoid receptors and the role of angiotensin II and glutamate in the paraventricular nucleus of rats with angiotensin II-induced hypertension.
    Gabor A; Leenen FH
    Hypertension; 2013 May; 61(5):1083-90. PubMed ID: 23509081
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Eplerenone promotes alternative activation in human monocyte-derived macrophages.
    Łabuzek K; Liber S; Bułdak Ł; Machnik G; Liber J; Okopień B
    Pharmacol Rep; 2013; 65(1):226-34. PubMed ID: 23563043
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Eplerenone: a new aldosterone receptor antagonist--are the FDAs restrictions appropriate?
    Sica DA
    J Clin Hypertens (Greenwich); 2002; 4(6):441-5. PubMed ID: 12461313
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New treatment option for heart failure patients: eplerenone.
    Southworth MR; Cavallari LH
    J Cardiovasc Nurs; 2004; 19(6):390-5. PubMed ID: 15529060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.